Travere Therapeutics (TVTX) Stock Price, News & Analysis

Company Overview

Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare kidney and immune-mediated diseases. The company’s work is centered on conditions with significant unmet medical needs, including diseases that can lead to progressive kidney damage and kidney failure.

Travere’s principal commercial product is FILSPARI (sparsentan), an oral therapy for adults with primary immunoglobulin A nephropathy, or IgA nephropathy, who are at risk of disease progression. FILSPARI is designed to reduce proteinuria, a key marker of kidney injury, and received U.S. regulatory approval for this indication. The company continues to study sparsentan and other potential therapies for kidney disorders.

The company was founded in 2008 as Retrophin and adopted the name Travere Therapeutics in 2020. Based in San Diego, California, Travere serves patients primarily through its U.S. commercial operations and pursues international opportunities through regulatory submissions and strategic partnerships. Eric Dube, Ph.D., serves as president and chief executive officer.

Key Stats

• Today's Range: $66.11 to $68.73
• 50-Day Range: $54.98 to $67.52
• 52-Week Range: $22.06 to $68.73
• Volume: 1.15 million shs
• Average Volume: 2.02 million shs
• Market Capitalization: $6.24 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $64.09
• Consensus Rating: Moderate Buy

Travere Therapeutics Stock Analysis - MarketRank™

Travere Therapeutics scored higher than 29% of companies evaluated by MarketBeat, and ranked 787th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Travere Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on no strong buy ratings, 10 buy ratings, 2 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Travere Therapeutics is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Travere Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Travere Therapeutics are expected to grow in the coming year, from ($0.54) to $2.63 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Travere Therapeutics is -143.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Travere Therapeutics is -143.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Travere Therapeutics has a P/B Ratio of 51.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.33% of the float of Travere Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Travere Therapeutics has a short interest ratio ("days to cover") of 9.56.

Change versus previous month

Short interest in Travere Therapeutics has recently increased by 0.51%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Travere Therapeutics does not currently pay a dividend.

Dividend Growth

Travere Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.30

News Sentiment

Travere Therapeutics has a news sentiment score of 1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Travere Therapeutics this week, compared to 5 articles on an average week.

Search Interest

Only 1 people have searched for TVTX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

MarketBeat Follows

2 people have added Travere Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Travere Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $725,700.00 in company stock.

Percentage Held by Insiders

4.44% of the stock of Travere Therapeutics is held by insiders.

Percentage Held by Institutions

Travere Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 9/11/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TVTX
• CIK: 1438533
• Web: www.travere.com
• Phone: (888) 969-7879
• Fax: 302-645-1280
• Employees: 497
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Travere Therapeutics: $64.09
• High Price Target: $85.00
• Low Price Target: $25.00
• Potential Upside/Downside: -3.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.69
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$25.55 million
• Net Margins: -7.35%
• Pretax Margin: -11.34%
• Return on Equity: -55.15%
• Return on Assets: -6.88%

Debt

• Debt-to-Equity Ratio: 24.58
• Current Ratio: 4.05
• Quick Ratio: 3.99

Sales & Book Value

• Annual Sales: $490.73 million
• Price / Sales: 12.71
• Cash Flow: $0.36 per share
• Price / Cash Flow: 182.86
• Book Value: $1.28 per share
• Price / Book: 51.70

Miscellaneous

• Outstanding Shares: 94,260,000
• Free Float: 90,076,000
• Market Cap: $6.24 billion
• Optionable: Optionable
• Beta: 1.05